How Long Does Cyclobenzaprine (Flexeril) Stay in Your System

Cyclobenzaprine (Flexeril) stays in your system for 3 to 4 days after your last dose, based on its half-life of 8 to 37 hours. 

Detection windows of cyclobenzaprine (flexeril) vary by test type: urine detects it for up to 4 days, blood for up to 16 hours, saliva for 36 to 48 hours, and hair follicle tests for up to 90 days.

The 10mg and 5mg doses share the same elimination timeline. Therapeutic effects wear off in 4 to 6 hours, but the drug continues metabolizing through CYP3A4 hepatic pathways for days after the last dose.

Age, liver function, dose frequency, and body fat percentage all significantly extend or shorten clearance time.

Key Takeaways

• Cyclobenzaprine (Flexeril) has a half-life of 8 to 37 hours, with a mean of approximately 18 hours. Full systemic clearance requires 3 to 4 days in healthy adults with normal hepatic function.
• According to FDA prescribing information, cyclobenzaprine is not detected on standard 5-panel SAMHSA urine screens. Extended panels may flag it as a tricyclic antidepressant due to its dibenzazepine chemical structure.
• The 10mg immediate-release dose produces therapeutic effects for 4 to 6 hours per dose. FDA labeling sets the maximum recommended treatment duration at 2 to 3 weeks.
• Cyclobenzaprine is metabolized by CYP3A4, CYP1A2, and CYP2D6 hepatic enzymes into the active metabolite norcyclobenzaprine, which extends CNS effects beyond what the parent compound half-life alone predicts.
• Long-term daily cyclobenzaprine use produces physical dependence through anticholinergic receptor adaptation. Abrupt cessation after prolonged use requires medically supervised tapering to prevent rebound muscle spasm and withdrawal symptoms.

What Is Cyclobenzaprine (Flexeril)?

Cyclobenzaprine is a dibenzazepine derivative prescribed as a short-term skeletal muscle relaxant for acute musculoskeletal pain and spasm, and is among the most frequently prescribed muscle relaxant medications in the United States.

Drug Class, Brand Names, and Available Doses

Cyclobenzaprine belongs to the dibenzazepine chemical class, structurally related to tricyclic antidepressants despite carrying no antidepressant indication. It is sold as Flexeril in immediate-release 5mg and 10mg tablets, and as Amrix in extended-release 15mg and 30mg capsules. Immediate-release formulations generate the detection data most relevant to drug testing and clearance timeline questions.

Cyclobenzaprine is FDA-approved for short-term use only, defined as 2 to 3 weeks. It is not a federally scheduled controlled substance and is not a narcotic, benzodiazepine, or opioid.

How Cyclobenzaprine Works: Mechanism and Active Metabolite

Cyclobenzaprine reduces skeletal muscle spasm by acting on brainstem and spinal cord motor neurons through noradrenergic modulation. It inhibits alpha and gamma motor neuron activity, reducing the tonic muscle hyperactivity responsible for painful spasm. Anticholinergic receptor binding produces sedation, dry mouth, and urinary retention as characteristic side effects.

Hepatic metabolism generates norcyclobenzaprine, the primary active metabolite. Norcyclobenzaprine contributes to extended CNS effects including next-day sedation during multi-dose regimens, particularly when doses accumulate faster than the body can eliminate them.

Cyclobenzaprine Half-Life and Clearance Timeline

Cyclobenzaprine has a half-life of 8 to 37 hours, with full systemic clearance requiring 3 to 4 days in adults with normal hepatic function. The wide half-life range reflects individual variation in CYP3A4 enzyme activity, liver health, and age.

Numbered Clearance Timeline After the Last Dose

Cyclobenzaprine clears from the body in the following sequence after the final dose:

1. 0 to 6 hours: Peak plasma concentration. Therapeutic muscle relaxant effects are maximal. Sedation, dry mouth, and dizziness are most pronounced during this window.
2. 6 to 18 hours: Plasma concentration declines by 50% per half-life cycle. Blood and saliva remain positive. Residual sedation persists in most patients throughout this phase.
3. 18 to 48 hours: Blood and saliva concentrations fall below standard detection thresholds. Urine remains the most reliable detection matrix during this period.
4. 48 to 96 hours (2 to 4 days): Full systemic clearance occurs in most adults with normal hepatic function. Urine detection approaches the lower limit of standard immunoassay sensitivity at this point.
5. Beyond 4 days: Measurable concentrations persist only in patients with hepatic impairment, high body fat, or extended treatment histories. Hair follicle detection remains positive for up to 90 days regardless of clearance in other matrices.

CYP3A4 Metabolism and the Norcyclobenzaprine Factor

Cyclobenzaprine undergoes extensive first-pass hepatic extraction through CYP3A4, CYP1A2, and CYP2D6 enzyme pathways. CYP3A4 is the primary route, generating norcyclobenzaprine as the principal circulating metabolite in most patients. Drugs inhibiting CYP3A4, including certain azole antifungals, erythromycin, and grapefruit compounds, substantially elevate plasma concentrations and extend the systemic detection window.

Smokers and patients on CYP1A2 inducers, such as rifampin, metabolize cyclobenzaprine faster than non-smokers. This accelerated clearance shortens both therapeutic duration and the urine detection window proportionally.

Cyclobenzaprine Detection Windows by Test Type

Cyclobenzaprine detection windows differ substantially by test type, from hours in blood to months in hair follicles.

Test Type	Detection Window	Key Notes
Urine	Up to 4 days	Most common; not on standard 5-panel
Blood	Up to 10 to 16 hours	Confirms very recent use only
Saliva	Up to 36 to 48 hours	Reflects active impairment window
Hair follicle	Up to 90 days	Historical use only; not dose-specific

Urine Drug Test Detection Window

Urine is the most commonly used matrix for cyclobenzaprine detection in employment, legal, and clinical settings. Standard SAMHSA 5-panel and 10-panel screens do not include cyclobenzaprine. Extended panels specifically requesting it detect the drug for 2 to 4 days after a single dose and up to 5 days after prolonged high-dose use.

Cyclobenzaprine cross-reacts with tricyclic antidepressant antibodies on immunoassay urine screens due to its dibenzazepine structure. Confirmatory GC-MS or LC-MS/MS testing clearly distinguishes cyclobenzaprine from true tricyclic antidepressants.

Blood and Saliva Detection Windows

Blood testing detects cyclobenzaprine only within 10 to 16 hours of the last dose, making it useful exclusively for confirming very recent use. Blood panels appear in impaired driving investigations and emergency settings rather than routine employment screening. The active metabolite norcyclobenzaprine persists in blood slightly longer than the parent compound, modestly extending the total detection window.

Saliva testing detects cyclobenzaprine for 36 to 48 hours after the last dose. Saliva reflects the active drug-related impairment window most accurately, making it the preferred matrix for roadside impaired driving assessments.

Hair Follicle Test Detection Window

Hair follicle testing detects cyclobenzaprine for up to 90 days, covering the standard retrospective window for most hair drug panels. Hair testing cannot pinpoint the timing of use within that 90-day window or establish current impairment. It confirms historical exposure only, without identifying specific dose timing or frequency.

DOT Drug Test and Military Screening

DOT (Department of Transportation) drug testing follows the federal 5-panel protocol covering marijuana, cocaine, amphetamines, opiates, and phencyclidine. Cyclobenzaprine is not included in DOT testing. CDL holders and safety-sensitive federal workers are not screened for cyclobenzaprine under DOT regulations, even though the drug impairs driving through sedation and slowed reaction time.

Military drug testing panels vary by branch and testing context. Most standard military panels do not include cyclobenzaprine by default. Branches may add it to expanded panels for specific populations or following safety incidents.

Does Cyclobenzaprine Show Up on a Drug Test?

Cyclobenzaprine does not appear on standard 5-panel or 10-panel SAMHSA drug tests, but extended panels can detect it, and its dibenzazepine structure produces false positive results for tricyclic antidepressants on immunoassay urine screening.

What Does Cyclobenzaprine Show Up As?

Cyclobenzaprine cross-reacts with tricyclic antidepressant antibodies in immunoassay-based urine screens. The test reports a presumptive TCA positive because cyclobenzaprine’s dibenzazepine structure resembles amitriptyline and nortriptyline at the antibody binding level. GC-MS confirmatory testing identifies the specific compound, definitively resolving the false positive result.

Individuals prescribed cyclobenzaprine should disclose their prescription before testing and provide documentation. Disclosed prescription records prevent adverse consequences from a cross-reactive immunoassay result on any extended or specialized panel.

Will Cyclobenzaprine 10mg Show Up on a Drug Test?

The 10mg dose follows the same detection rules as the 5mg dose. It does not appear on standard SAMHSA tests and may cross-react with TCA immunoassays on extended panels. Higher doses modestly extend the urine detection window from 3 days toward the upper 4-to-5-day range.

A single 10mg dose in a healthy adult with normal hepatic function is typically undetectable in urine within 3 to 4 days of ingestion.

How Long Does Cyclobenzaprine Last vs. Stay in Your System?

Cyclobenzaprine’s therapeutic effects last 4 to 6 hours per dose, while the drug remains in the body and detectable in urine for 3 to 4 days, a critical distinction between effect duration and full elimination time.

How Long Does the 10mg Dose Last?

The 10mg immediate-release dose reaches peak therapeutic muscle relaxation within 1 to 2 hours of ingestion and maintains clinical effectiveness for 4 to 6 hours. Most patients require three-times-daily dosing to sustain coverage through waking hours. Next-day residual sedation from evening doses is common because norcyclobenzaprine accumulates during multi-dose regimens faster than the body eliminates it.

How Long Does the 5mg Dose Last?

The 5mg dose reaches peak plasma concentration in 1 to 2 hours and produces 4 to 6 hours of therapeutic effect per dose. Total drug exposure is approximately half that of the 10mg dose, generating less sedation and a modestly shorter residual effect duration. The FDA approves 5mg as the preferred starting dose for elderly patients and those using concurrent alcohol or other CNS depressants.

Next-Day Sedation: How Long Does Cyclobenzaprine Make You Tired?

Cyclobenzaprine causes next-day tiredness through norcyclobenzaprine accumulation during multi-dose regimens. When taken three times daily, the active metabolite builds up faster than it clears, producing morning drowsiness, cognitive slowing, and impaired reaction time the following day. Patients should assess their individual response before driving or operating machinery each morning during treatment.

Factors That Affect How Long Cyclobenzaprine Stays in Your System

Liver function, age, body fat percentage, dose frequency, and concurrent medications all significantly extend or shorten cyclobenzaprine clearance time in clinically meaningful ways.

Liver Health and Hepatic Impairment

Cyclobenzaprine undergoes extensive hepatic metabolism with minimal unchanged renal excretion. Patients with hepatic impairment accumulate substantially higher cyclobenzaprine and norcyclobenzaprine plasma concentrations than those with normal liver function. The FDA advises caution in mild hepatic impairment and recommends avoiding cyclobenzaprine entirely in moderate to severe cases.

Renal disease modestly slows glucuronidated metabolite excretion. Combined hepatic and renal impairment substantially extends cyclobenzaprine’s systemic presence beyond standard clearance estimates.

Age and Body Fat Percentage

Elderly patients clear cyclobenzaprine more slowly due to reduced CYP3A4 expression and lower hepatic metabolic capacity with aging. Plasma concentrations in patients over 65 are substantially higher than in younger adults at identical doses. The FDA specifically warns that elderly patients face elevated risk for sedation, confusion, cardiac arrhythmias, and falls.

Higher body fat percentage increases cyclobenzaprine’s volume of distribution due to its lipophilic properties. Greater lipid distribution extends the elimination half-life, delaying overall systemic clearance regardless of dose or treatment duration.

Is Cyclobenzaprine Hard on Your Body? Organ Effects

Cyclobenzaprine imposes anticholinergic burden on the liver, bladder, cardiovascular system, and CNS throughout treatment. Hepatic enzyme elevations are documented in clinical literature, establishing cyclobenzaprine as a drug requiring liver function consideration during extended courses. Patients with fatty liver disease or elevated baseline transaminases require monitoring.

Long-term anticholinergic exposure also produces urinary retention, cognitive impairment, and tachycardia in susceptible patients. Unlike tizanidine, which produces organ burden through alpha-2 adrenergic pathways, cyclobenzaprine’s organ effects arise through tricyclic-like anticholinergic mechanisms.

Cyclobenzaprine Dependence and Withdrawal

Cyclobenzaprine produces physical dependence through sustained anticholinergic and CNS depressant receptor adaptation during daily use. The DSM-5 criteria for a substance use disorder can be satisfied when escalating doses, failed cessation attempts, and continued use despite documented harm are all present. Prescription drug dependence on cyclobenzaprine is most common in patients who exceed the FDA-recommended 2-to-3-week treatment limit.

Abrupt cessation after prolonged use produces rebound muscle spasm, anxiety, nausea, and insomnia. Gradual dose tapering over 1 to 2 weeks is the standard clinical approach to cyclobenzaprine discontinuation after sustained daily use.

Treatment for Cyclobenzaprine Dependence at The Grove Estate

The Grove Estate Addiction Treatment provides medically supervised care for adults with muscle relaxant dependence, including cyclobenzaprine use disorder, at its Indiana residential facility.

1- Medical Detox

Medical detox at The Grove Estate provides 24-hour physician-supervised management of cyclobenzaprine withdrawal, including monitoring for rebound muscle spasm, anticholinergic rebound, and cardiovascular effects during acute discontinuation. Structured tapering protocols reduce withdrawal severity for patients who used cyclobenzaprine beyond the recommended treatment duration. Same-day assessments are available for patients presenting in acute prescription drug withdrawal.

2- Residential Addiction Treatment

Residential addiction treatment at The Grove Estate removes patients from cyclobenzaprine access during the highest-risk period of early recovery, when physical dependence and behavioral cravings are most intense. Individual therapy, Cognitive Behavioral Therapy groups, and relapse prevention programming address prescription muscle relaxant dependence specifically. Therapist continuity from detox through residential care reduces relapse risk during early abstinence when withdrawal symptoms peak.

3- Dual Diagnosis Treatment

Many patients who develop cyclobenzaprine dependence began using the drug to manage untreated chronic musculoskeletal pain, anxiety, or insomnia from an underlying condition. Dual diagnosis treatment at The Grove Estate addresses both the prescription drug dependence and any co-occurring medical or psychiatric conditions simultaneously. Integrated concurrent treatment produces substantially better long-term outcomes than addressing each condition separately.

Frequently Asked Questions

How Long Is Cyclobenzaprine Active?

Cyclobenzaprine is therapeutically active for 4 to 6 hours per immediate-release dose, whether 5mg or 10mg. It reaches peak plasma concentration within 1 to 2 hours. The extended-release Amrix formulation maintains therapeutic levels for up to 24 hours per dose. Active therapeutic effect and total elimination time differ significantly: the drug remains in the body for 3 to 4 days after the final dose.

Is Cyclobenzaprine Hard on Your Body?

Yes. Cyclobenzaprine imposes anticholinergic burden on the liver, bladder, heart, and central nervous system. Hepatic enzyme elevations are documented with use. Elderly patients face elevated risk for falls, confusion, urinary retention, and cardiac arrhythmias. The FDA restricts use to 2 to 3 weeks and advises against the drug in patients with moderate to severe hepatic impairment.

Will Cyclobenzaprine 10mg Show Up on a Drug Test?

Cyclobenzaprine 10mg does not appear on standard 5-panel or 10-panel urine drug tests. It may produce a false positive for tricyclic antidepressants on immunoassay-based extended panels due to its dibenzazepine structure. GC-MS confirmatory testing resolves this definitively. Specialized panels that include cyclobenzaprine detect the 10mg dose in urine for up to 3 to 4 days after the last dose.

Can Cyclobenzaprine Make You Tired the Next Day?

Yes. Cyclobenzaprine causes next-day sedation through norcyclobenzaprine accumulation during multi-dose regimens. When taken three times daily, the active metabolite accumulates faster than it clears, causing morning drowsiness, cognitive slowing, and impaired reaction time. Patients should assess their response before driving or operating machinery each morning, particularly during the first week of treatment when accumulation is greatest.

References

1. Food and Drug Administration. (2003). Flexeril (cyclobenzaprine hydrochloride) prescribing information. McNeil Consumer Healthcare. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/017821s034lbl.pdf
2. National Library of Medicine. (2023). Cyclobenzaprine. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a682514.html
3. Substance Abuse and Mental Health Services Administration. (2023). Mandatory guidelines for federal workplace drug testing programs. https://www.samhsa.gov/workplace/drug-testing
4. National Institute on Drug Abuse. (2022). Prescription CNS depressants drug facts. https://nida.nih.gov/publications/drugfacts/prescription-cns-depressants
5. Toth, P. P., & Urtis, J. (2004). Commonly used muscle relaxant therapies for acute low back pain: A review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clinical Therapeutics, 26(9), 1355-1367.
6. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing.
7. American Geriatrics Society. (2019). American Geriatrics Society 2019 Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 67(4), 674-694.